title: [Docetaxel for metastatic prostate cancer: early is better].
abstract: Androgen deprivation therapy (ADT) has been used to treat patients with metastatic prostate cancer for many years. Docetaxel chemotherapy administered to patients with metastatic castrate-resistant prostate cancer has been standard since 2004 with a modest survival benefit. Recent data from two randomised studies (CHAARTED and STAMPEDE) demonstrate that combining ADT with docetaxel in men with hormone-naïve metastatic prostate cancer resulted in an impressive overall survival benefit of more than a year as compared with ADT alone. In a meta-analysis, the consistency of these data was confirmed. On the basis of these data, addition of six 3-weekly courses of docetaxel to ADT should be considered as standard treatment in chemo-fit patients with hormone-naïve metastatic prostate cancer.
authors.affiliation: Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen Comprehensive Cancer Center, afd. Medische Oncologie, Groningen.
authors.forename: J A
authors.initials: JA
authors.lastname: Gietema
authors.forename: S F
authors.initials: SF
authors.lastname: Oosting
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel